Foghorn Therapeutics (FHTX) PT Raised to $28 at Goldman Sachs, Following Clinical Update
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Goldman Sachs analyst Paul Choi raised the price target on Foghorn Therapeutics (NASDAQ: FHTX) to $28.00 (from $27.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- flatexDEGIRO AG (FTKn:GR) (FNNTF) PT Raised to EUR120 at Goldman Sachs
- ESR Cayman Ltd (1821:HK) (ESRCF) PT Raised to HK$29.20 at Morgan Stanley
- KB Financial Group (105560:KS) (KB) PT Raised to KRW67,500 at Morgan Stanley